for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.OQ

Latest Trade

195.65USD

Change

0.61(+0.31%)

Volume

641,797

Today's Range

194.70

 - 

196.37

52 Week Range

166.30

 - 

211.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
195.04
Open
195.68
Volume
641,797
3M AVG Volume
66.58
Today's High
196.37
Today's Low
194.70
52 Week High
211.89
52 Week Low
166.30
Shares Out (MIL)
599.70
Market Cap (MIL)
117,973.20
Forward P/E
13.74
Dividend (Yield %)
2.95

Next Event

Q3 2019 Amgen Inc Earnings Release

Latest Developments

More

Amgen Announces Phase 3 Candor Study Combining Kyprolis And Darzalex Meets Primary Endpoint Of Progression-Free Survival

Amgen Highlights New Data From Kyprolis (Carfilzomib) And Oncology Pipeline At IMW 2019

Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

+1.805.4471000

http://www.amgen.com

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

David W. Meline

Executive Vice President, Chief Financial Officer

Murdo Gordon

Executive Vice President of Global Commercial Operations

David M. Reese

Executive Vice President - Research and Development

Esteban Santos

Executive Vice President, Operations

Key Stats

2.32 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.8K

2018

23.7K

2019(E)

22.8K
EPS (USD)

2016

11.650

2017

12.580

2018

14.400

2019(E)

14.320
Price To Earnings (TTM)
15.58
Price To Sales (TTM)
5.01
Price To Book (MRQ)
10.97
Price To Cash Flow (TTM)
11.86
Total Debt To Equity (MRQ)
283.62
LT Debt To Equity (MRQ)
257.53
Return on Investment (TTM)
15.12
Return on Equity (TTM)
12.53

Latest News

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

Patent court to review Alexion's Soliris patents on Amgen challenge - filings

The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Sanofi in Amgen patent fight

A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

U.S. court upholds Amgen patents on arthritis drug Enbrel

A U.S. judge on Friday said patents relating to the Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

Amgen results beat estimates, lung cancer trial planned

Amgen Inc <AMGN.O> on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

Amgen quarterly revenue dips 3% but profit tops Street expectations

Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

BRIEF-Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With Bace Inhibitor Cnp520 For Alzheimer's Prevention

* AMGEN, NOVARTIS AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL RESEARCH PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION

BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520

* CO, AMGEN AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION Source text for Eikon: Further company coverage:

BRIEF-Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA

* AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly...

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.

Amgen to buy Copenhagen-based Nuevolution for $167 million

Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

Amgen offers to buy Copenhagen-based Nuevolution for $167 mln

Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in...

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up